The Anti-Parkinson Drugs Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
What are the Historical Growth Trends in the Anti-Parkinson Drugs Market?
The market for anti-parkinson drugs has witnessed robust growth in the past years. It is projected to expand from a value of $10.37 billion in 2024 to $11.08 billion in 2025, with a compound annual growth rate (CAGR) of 6.9%.
What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Anti-Parkinson Drugs Industry?
The Anti-Parkinson Drugs Global Market is predicted to increase to a market size of $13.73 billion by 2029, with a compound annual growth rate (CAGR) of 5.5%.
Download Your Free Sample of the 2025 Anti-Parkinson Drugs Market Report and Uncover Key Trends Now!
What are the Key Growth Drivers Fueling the Anti-Parkinson Drugs Market?
The key drivers in the anti-parkinson drugs market are:
• Increasing public awareness about Parkinson's disease
• Advancements in biotechnology
• The emergence of new market territories
• Increased investment in research and development activities related to the disease.
Global Market Segmentation: Identifying Major Anti-Parkinson Drugs Industry Segments
The anti-parkinson drugs market covered in this report is segmented –
1) By Drugs Class: Levodopa Or Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics, Other Drugs
2) By Route of Administration: Oral, Injection, Transdermal
3) By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies
Pre-order the 2025 Anti-Parkinson Drugs Global Market Report for Fast Delivery & Comprehensive Insights!
What are the Emerging Trends Shaping the Future of the Anti-Parkinson Drugs Market?
The key trends in the anti-parkinson drugs market are:
• Increased investment in research and development is a notable trend.
• Personalized medicine is becoming more prevalent in the anti-Parkinson drug market.
• Disease-modifying therapies are emerging as a significant trend.
• Telemedicine and remote monitoring are fast-growing trends in the market.
Who Are the Top Competitors & Leading Players in the Anti-Parkinson Drugs Market?
Major companies in the anti-parkinson drugs market are:
• GlaxoSmithKline plc
• Pfizer Inc.
• Merck Co.
• Novartis AG
• F. Hoffmann-La Roche AG
• UCB S.A
• Teva Pharmaceutical Industries Ltd.
• AbbVie Inc.
• Mylan NV
• C.H. Boehringer Sohn AG & Co. KG
• Orion Pharma Ltd.
• ACADIA Pharmaceuticals Inc.
• Sun Pharmaceutical Industries Ltd.
• Wockhardt Ltd.
• Reddy's Laboratories Ltd.
• Intas Pharmaceuticals Ltd.
• US WorldMeds LLC
• Zydus Lifesciences Limited
• Chemical Industrial & Pharmaceutical Laboratories Ltd.
• Strides Shasun Ltd.
• Axcan Pharma Inc.
• Upsher-Smith Laboratories LLC
• H. Lundbeck A/S
• Vertical Pharmaceuticals LLC
• Zambon SPA
• M Somerset Pharmaceuticals Inc.
• Valeant Pharmaceuticals International Inc.
• Neurocrine Biosciences Inc.
• Supernus Pharmaceuticals Inc.
Regional Dominance: Which Area Leads the Global Anti-Parkinson Drugs Market?
North America was the largest region in the anti-Parkinson drugs market in 2023
